Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rani Therapeutics Holdings (RANI) Net Margin (2020 - 2026)

Rani Therapeutics Holdings' Net Margin history spans 5 years, with the latest figure at 469.26% for Q1 2026.

  • On a quarterly basis, Net Margin rose 693655.0% to 469.26% in Q1 2026 year-over-year; TTM through Mar 2026 was 1124.99%, a 342026.0% increase, with the full-year FY2025 number at 2472.38%, up 303190.0% from a year prior.
  • Net Margin came in at 469.26% for Q1 2026, up from 581.66% in the prior quarter.
  • The five-year high for Net Margin was 469.26% in Q1 2026, with the low at 7405.81% in Q1 2025.
  • Historically, Net Margin has averaged 2496.53% across 3 years, with a median of 1055.52% in 2024.
  • Biggest five-year swings in Net Margin: surged 94772bps in 2025 and later skyrocketed 693655bps in 2026.
  • Year by year, Net Margin stood at 1529.38% in 2024, then soared by 62bps to 581.66% in 2025, then increased by 19bps to 469.26% in 2026.
  • Business Quant data shows Net Margin for RANI at 469.26% in Q1 2026, 581.66% in Q4 2025, and 7405.81% in Q1 2025.